![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2023
Anzahl der Publikationen: 1
2023
Holzgreve, Adrien 
ORCID: https://orcid.org/0000-0002-9566-8438; Unterrainer, Marcus; Calais, Jérémie; Adams, Thaiza; Oprea-Lager, Daniela E.; Goffin, Karolien; Lopci, Egesta; Unterrainer, Lena M.; Kramer, Kristina K. M.; Schmidt-Hegemann, Nina-Sophie; Casuscelli, Jozefina; Stief, Christian G. ORCID: https://orcid.org/0000-0003-3291-9460; Ricke, Jens; Bartenstein, Peter; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952 und Mehrens, Dirk
(2023):
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 50, Nr. 12: S. 3750-3754
[PDF, 616kB]
ORCID: https://orcid.org/0000-0002-9566-8438; Unterrainer, Marcus; Calais, Jérémie; Adams, Thaiza; Oprea-Lager, Daniela E.; Goffin, Karolien; Lopci, Egesta; Unterrainer, Lena M.; Kramer, Kristina K. M.; Schmidt-Hegemann, Nina-Sophie; Casuscelli, Jozefina; Stief, Christian G. ORCID: https://orcid.org/0000-0003-3291-9460; Ricke, Jens; Bartenstein, Peter; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952 und Mehrens, Dirk
(2023):
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 50, Nr. 12: S. 3750-3754
[PDF, 616kB]